TheLion.com - Forum

From: tothedeath (Rep: 9) reply to DrSilkworth2002

Date: 09/12/2009 17:17

Forum: Anadys Pharmaceuticals - Msg #853

Thread #672748634 (Rec: 0)

Re: Notes from Rodman & Renshaw conference

Good stuff, thx Doc.

Share This Post:

Reply to DrSilkworth2002 - Msg #852 - 09/12/2009 08:52

Notes from Rodman & Renshaw conference

* Tested rats for 6 months. Monkeys for 9 months
* ANA598 being developed for an important unmet need.
* Less than 50% of patients respond to treatment in clinical trials. A lower percentage respond in real world practice.
* Current real world treatments are difficult to take.
* ANA598 future use will be for 2 kinds of patients. Naive patients currently taking existing treatments will use ANA598 to improve response and shorten duration of existing difficult treatment. Prior patients who failed previous treatment will have a chance to use previous treatments in combination with ANA598. Data shows improved cure rate. More work to be done in this area.
* 2 to 3 billion dollar HCV market with 10 billion as up side.
* Currently several companies working on ways to block viral replication but this is less of a differentiating feature than safety and tolerability of agents. This is where Anadys plans to shine.
* Key data in phase II will be percentage of patients with undetectable virus at weeks 4 and 12.
* Key data in phase II will be 28 day safety read.
* Clean toxicology report on Monkeys at 3 months. They expect the 9 month results to be consistent. Rat study went well too. Only one female rat didn't gain as much weight during the study. Didn't loose weight....just didn't gain as much as the others in the study. Full results due this month.
* Reiterated the are funded into 2011. Closed 2Q09 with 30.6 million cash. They have no debt.
* The future holds consolidation. The plan is to fold ANA598 into a combination treatment with another company(s) to provide best treatment with shorter duration, safe and tolerable. He said they plan to use the same business model as Gilead in reference how they combined treatments with other companies to make the best treatment. Options are open for now on how they will monetize this.
* ANA773 is in development as an oral replacement for interferon alpha that is better tolerated and works well with other treatments in development. Currently looking for a partner for this project.
* ANA598 will prove to be more potent in combination. The other treatments will be more potent in combination with ANA598. Win/win situation if it passes FDA.

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser tothedeath: Reward | Watch | IgnoreANDS: Ignore